![Cara Therapeutics logo](/news-release/logo/311292/0/311292.jpg?lastModified=12%2F09%2F2016%2023%3A24%3A14&size=2)
Cara Therapeutics Announces Positive Top-Line Results From Phase 2a Trial of Oral CR845 in Chronic Pain Patients With Osteoarthritis of the Knee or Hip
09 déc. 2015 07h00 HE
|
Cara Therapeutics
Dose-related reduction observed in mean baseline pain score up to 34 percent after two weeks, with statistically significant reduction in mean rescue medication for top 5.0 mg dose
All four...
![Cara Therapeutics logo](/news-release/logo/311292/0/311292.jpg?lastModified=12%2F09%2F2016%2023%3A24%3A14&size=2)
Cara Therapeutics to Present Poster at the ASHP 2015 Midyear Clinical Meeting
01 déc. 2015 08h00 HE
|
Cara Therapeutics
SHELTON, Conn., Dec. 1, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate...
![Cara Therapeutics logo](/news-release/logo/311292/0/311292.jpg?lastModified=12%2F09%2F2016%2023%3A24%3A14&size=2)
Cara Therapeutics to Webcast Presentation at the Piper Jaffray 27th Annual Healthcare Conference
25 nov. 2015 08h00 HE
|
Cara Therapeutics
SHELTON, Conn., Nov. 25, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate...
![Cara Therapeutics logo](/news-release/logo/311292/0/311292.jpg?lastModified=12%2F09%2F2016%2023%3A24%3A14&size=2)
Cara Therapeutics to Webcast Presentation at the Stifel 2015 Healthcare Conference
11 nov. 2015 08h00 HE
|
Cara Therapeutics
SHELTON, Conn., Nov. 11, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate...
![Cara Therapeutics logo](/news-release/logo/311292/0/311292.jpg?lastModified=12%2F09%2F2016%2023%3A24%3A14&size=2)
Cara Therapeutics Reports Third Quarter 2015 Financial Results
09 nov. 2015 16h01 HE
|
Cara Therapeutics
– Initiated Phase 3 program for I.V. CR845 in acute postoperative pain –
– Initiated Phase 2a trial of Oral CR845 in osteoarthritis patients –
– Earned $2.75M in...
![Cara Therapeutics logo](/news-release/logo/311292/0/311292.jpg?lastModified=12%2F09%2F2016%2023%3A24%3A14&size=2)
Cara Therapeutics to Announce Third Quarter 2015 Financial Results on November 9, 2015
02 nov. 2015 16h30 HE
|
Cara Therapeutics
SHELTON, Conn., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate...
![Cara Therapeutics logo](/news-release/logo/311292/0/311292.jpg?lastModified=12%2F09%2F2016%2023%3A24%3A14&size=2)
Cara Therapeutics to Present Late-Breaking Poster at Kidney Week 2015
29 oct. 2015 08h00 HE
|
Cara Therapeutics
SHELTON, Conn., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate...
![Cara Therapeutics logo](/news-release/logo/311292/0/311292.jpg?lastModified=12%2F09%2F2016%2023%3A24%3A14&size=2)
Cara Therapeutics to Present at 2nd Human Abuse Liability & Abuse-Deterrent Formulations Conference
26 oct. 2015 08h00 HE
|
Cara Therapeutics
Chief Medical Officer Dr. Joseph Stauffer to discuss potential for kappa opioids
SHELTON, Conn., Oct. 26, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology...
![Cara Therapeutics logo](/news-release/logo/311292/0/311292.jpg?lastModified=12%2F09%2F2016%2023%3A24%3A14&size=2)
Cara Therapeutics to Sponsor Symposium and Present Poster at ANESTHESIOLOGY 2015
19 oct. 2015 08h00 HE
|
Cara Therapeutics
Pain experts to discuss trends in kappa opioid receptor agonists and the future of postoperative pain management
Company to present positive data from Phase 2 acute pain trials of I.V....
![Cara Therapeutics logo](/news-release/logo/311292/0/311292.jpg?lastModified=12%2F09%2F2016%2023%3A24%3A14&size=2)
Cara Therapeutics Achieves Milestone Payments From Japan and South Korea Partners for Development of CR845 in Uremic Pruritus
13 oct. 2015 08h00 HE
|
Cara Therapeutics
$2.5M Milestones Earned for Advancement of CR845 in Phase 2 Clinical Trials in U.S. and Japan
SHELTON, Conn., Oct. 13, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a...